Skip to main content

AlcoDigital and Renault Trucks partner to prevent drink driving deaths

Alcohol safety and training specialist AlcoDigital (AD) has joined forces with Renault Trucks to showcase and offer a new safety device in their latest range of LCV Master business fleet vehicles, which will feature at the Freight in the City Exhibition 7 November 2017. The alcohol safety device, Draeger Interlock 7000, will monitor drivers by requiring them to pass a breathalyzer test before they start the engine.
October 13, 2017 Read time: 2 mins
Alcohol safety and training specialist AlcoDigital (AD) has joined forces with 2453 Renault Trucks to showcase and offer a new safety device in their latest range of LCV Master business fleet vehicles, which will feature at the Freight in the City Exhibition 7 November 2017.

The alcohol safety device, 8299 Draeger Interlock 7000, will monitor drivers by requiring them to pass a breathalyzer test before they start the engine. If the driver fails the test, the interlock will automatically disable the vehicle for a pre-specified amount of time set by the company. The device can then request further tests throughout the journey. It can also be included as an upgraded extra at the customer’s request.

If provided separately, the current retail price is around £1,500 + VAT before fitting, however, Renault customers who wish to upgrade their fleet will be offered a discount as part of the initiative.

Suzannah Robin, alcohol and drug expert at AD said, “As many as 6,500 deaths could be prevented annually if drink driving was eliminated in Europe and several studies have already shown that an alcohol interlock fitted to a vehicle, where a driver has to pass a breath test prior to being allowed to start the engine, has been very effective in cutting repeat drink driving offences.”

UTC

Related Content

  • January 25, 2018
    Enforcement ensures equity for toll road users
    All-electronic tolling boosts traffic flow but introduces the tricky question of enforcement. Workable solutions are starting to emerge. Enforcement is an essential part of tolling and one of the most important ways for a mobility agency to keep faith with its investors, its community stakeholders and the vast majority of its users. It can also be one of the most unpopular and contentious things a toll authority has to undertake. If tolling is about paying for the roads, then everyone has to pay their
  • March 4, 2019
    Transport Systems Catapult boss: ‘We can’t build our way out of congestion’
    The UK Transport Systems Catapult’s CEO Paul Campion talks to Colin Sowman about helping companies develop tomorrow’s solutions – and explains why you can never build your way to empty roads The future of mobility is going to be driven by services.” That’s the opening position of Paul Campion, CEO of the Transport Systems Catapult (TSC) – the UK government organisation set up to help boost transport-related employment and the economy. Campion was previously with IBM and describes himself as a ‘techno o
  • September 4, 2018
    ASECAP examines tolling’s trials, tribulations and triumphs
    If you want to get up to speed on the main issues facing the transport sector and tolling companies, ASECAP Study Days event in Ljubljana was a good place to start. Colin Sowman reports (Photographs: Louis David). Increasing populations, ever-higher technical and safety requirements, and electric and hybrid vehicles will provide both challenges and opportunities for tolling companies. The annual Study Days event organised by ASECAP (the European association for tolling companies) examined all of these aspec
  • August 21, 2019
    Canada puts $2.5m into tackling drug-impaired driving
    The government of Canada is investing CAN$2.5 million over five years to tackle drug-impaired driving in the province of Prince Edward Island. The move is part of a CAN$81 million package to support public and road safety activities. Funding will help train more police officers in standardised field sobriety testing and drug recognition expert evaluation. The money will also be used to purchase approved drug screening devices and develop standardised data collection and reporting practices to analyse